The operator of a Vietnamese mine has filed a lawsuit seeking to enforce a $132 million arbitration judgment against engineering company Jacobs E&C, which was acquired by WorleyParsons in December.
Former Aussie Home Loans boss Stephen Porges has lost an appeal of a judgment ordering him to pay more than $1 million to a private equity firm that was found to have been duped into buying his worthless shares in a beleaguered startup.
The founder and former CEO of Smiles Inclusive has been taken to court by the dental company, which accuses him of serious misconduct over allegedly unlawful payments and transactions.
James Cook University unlawfully dismissed a professor who spoke out against the school and one of its scientists over its climate change views, a judge found Tuesday.
A director of an energy company who was kicked off the board for missing too many meetings has filed an appeal of a ruling dismissing his case over delays in complying with court requests after his lawyer from Maddocks withdrew from the case due to late payments.
Dairy giant Parmalat has come up short in its attempt to block competitor The a2 Milk Company from registering a trade mark in Australia for a logo featuring the words “A2/A2 Genetics Verification”.
The Australian Competition and Consumer Commission has brought legal action against Bupa alleging the aged care provider charged thousands of residents for promised extra services it did not provide.
An Australian marketing company that allows clients to schedule socal media posts has won a temporary court injunction against Facebook and Instagram in a lawsuit alleging a decision to block the startup from their platforms is a misuse of market power.
Citigroup has agreed to refund $3 million to 114 customers that suffered losses stemming from investments in complex financial products, after ASIC raised concerns that some of the customers may have thought they were getting personal rather than general advice.
Generic drug maker Sandoz has secured a retroactive licence to manufacture a cheaper version of top-selling antidepressant Lexapro, the drug at the heart of a long-running patent infringement battle with pharmaceutical giant Lundbeck.